335 related articles for article (PubMed ID: 28915080)
1. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
3. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
Máspero J
Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
[TBL] [Abstract][Full Text] [Related]
4. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
5. Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
Can Respir J; 2019; 2019():8607657. PubMed ID: 31885750
[TBL] [Abstract][Full Text] [Related]
6. Activated sputum eosinophils associated with exacerbations in children on mepolizumab.
Wilson GE; Knight J; Liu Q; Shelar A; Stewart E; Wang X; Yan X; Sanders J; Visness C; Gill M; Gruchalla R; Liu AH; Kattan M; Khurana Hershey GK; Togias A; Becker PM; Altman MC; Busse WW; Jackson DJ; Montgomery RR; Chupp GL
J Allergy Clin Immunol; 2024 Mar; ():. PubMed ID: 38485057
[TBL] [Abstract][Full Text] [Related]
7. Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.
Mukherjee M; Lim HF; Thomas S; Miller D; Kjarsgaard M; Tan B; Sehmi R; Khalidi N; Nair P
Allergy Asthma Clin Immunol; 2017; 13():2. PubMed ID: 28070196
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
9. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
Sahota J; Robinson DS
Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
[TBL] [Abstract][Full Text] [Related]
10. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
11. Prospective direct comparison of biologic treatments for severe eosinophilic asthma: Findings from the PRISM study.
Pham DD; Lee JH; Kwon HS; Song WJ; Cho YS; Kim H; Kwon JW; Park SY; Kim S; Hur GY; Kim BK; Nam YH; Yang MS; Kim MY; Kim SH; Lee BJ; Lee T; Park SY; Kim MH; Cho YJ; Park C; Jung JW; Park HK; Kim JH; Moon JY; Adcock I; Bhavsar P; Chung KF; Kim TB
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):457-462.e2. PubMed ID: 37977324
[TBL] [Abstract][Full Text] [Related]
12. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics.
Langton D; Politis J; Collyer T; Khung SW; Bardin P
Respirology; 2023 Dec; 28(12):1117-1125. PubMed ID: 37638723
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis.
Henriksen DP; Bodtger U; Sidenius K; Maltbaek N; Pedersen L; Madsen H; Andersson EA; Norgaard O; Madsen LK; Chawes BL
Eur Clin Respir J; 2018; 5(1):1536097. PubMed ID: 30533206
[No Abstract] [Full Text] [Related]
14. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation.
Reilly C; Raja A; Anilkumar P; Sullivan J; White L; Bahron A; Marsh J; Mansur AH
J Asthma; 2024 Jun; 61(6):561-573. PubMed ID: 38088937
[TBL] [Abstract][Full Text] [Related]
15. Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5.
Moermans C; Brion C; Bock G; Graff S; Gerday S; Nekoee H; Poulet C; Bricmont N; Henket M; Paulus V; Guissard F; Louis R; Schleich F
Chest; 2023 Jun; 163(6):1368-1379. PubMed ID: 36740095
[TBL] [Abstract][Full Text] [Related]
16. Lung function trajectories in a cohort of patients with moderate-to-severe asthma on mepolizumab, omalizumab, or dupilumab.
Nopsopon T; Barrett NA; Phipatanakul W; Laidlaw TM; Weiss ST; Akenroye A
Allergy; 2024 May; 79(5):1195-1207. PubMed ID: 38164813
[TBL] [Abstract][Full Text] [Related]
17. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline.
Gerday S; Graff S; Moermans C; Guissard F; Paulus V; Henket M; Louis R; Schleich F
Thorax; 2023 Nov; 78(11):1138-1141. PubMed ID: 37657926
[TBL] [Abstract][Full Text] [Related]
18. Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma.
Tang M; Charbit AR; Johansson MW; Jarjour NN; Denlinger LC; Raymond WW; Peters MC; Dunican EM; Castro M; Sumino K; Erzurum SC; Comhair SA; Moore WC; Levy BD; Israel E; Phipatanakul W; Phillips BR; Mauger DT; Bleecker ER; Wenzel SE; Fajt ML; Woodruff PG; Hastie AT; Fahy JV;
J Allergy Clin Immunol; 2024 Apr; ():. PubMed ID: 38663815
[TBL] [Abstract][Full Text] [Related]
19. Blood CD62L
Vultaggio A; Accinno M; Vivarelli E; Mecheri V; Maggiore G; Cosmi L; Parronchi P; Rossi O; Maggi E; Gallo O; Matucci A
Allergy; 2023 Dec; 78(12):3154-3165. PubMed ID: 37792721
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
